2022 Annual Meeting - Managing Challenging Cases: Bladder Cancer
Bladder cancer is arguably the most challenging GU malignancy for radiation oncologists to manage, in part because outcomes are worse than other GU malignancies, patients have a high comorbid disease burden, and providers have less experience treating the disease. Radiation oncologists are treating more and more bladder cancer patients definitively and recent studies have shown the value of hypofractionated radiation which improves convenience as well as the value of concurrent chemoRT in the setting of high-risk, recurrent non-muscle invasive disease.
There is a clear need to provide a real-world educational workshop to discuss challenging cases that are of relevance to the radiation oncologist, presenting the latest cutting edge research to explain and provide context for management decisions. We would discuss 1) Challenges in the workup and staging of bladder cancer and the use of MRI and PET/CT scan 2) Challenging definitive RT cases with respect to unfavorable bowel anatomy or very elderly/infirm patients 3) Treatment planning/dose constraints for standard and hypofractionated RT 4) Role of adaptive radiation 5) Non-muscle-invasive disease 6) Node-positive disease 7) Oligometastatic recurrent disease 8) Squamous cell carcinoma of the bladder 9) Post-cystectomy RT.
The activity is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, radiation physicists and radiation oncology residents.
Upon completion of this activity, participants should be able to:
- Describe the value of MRI and PET/CT scan for staging and workup of bladder cancer and assess and manage clinical challenges in the treatment of muscle-invasive bladder cancer.
- Better manage challenging situations in bladder cancer in new and emerging areas, including node-positive disease, non-muscle invasive bladder cancer, post-cystectomy radiation, oligometastatic disease and squamous cell carcinoma of the bladder.
- Describe nuances of treatment planning for bladder cancer with respect to simulation, dose constraints, managing organ motion, dose/fractionation and clinical target volumes.
Brian Baumann, MD is employed at Washington University School of Medicine in St. Louis, Department of Radiation Oncology, St. Louis, MO and receives compensation/remuneration/funding from Galera Therapeutics, Mevion Medical Systems, Regeneron, Varian.
Jason Efstathiou, MD is employed at Department of Radiation Oncology, Harvard School of Medicine, Boston, MA and has no financial relationships with a commercial interest.
Vedang Murthy, MD is employed at Tata Memorial Hospital, Mumbai, India and has no financial relationships with a commercial interest.
Leslie Ballas, MD is employed at Department of Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.